DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 2 Justin Zelin - 2 Zelin - 2 drugmakers Roche - 1 Lilly - 1 Denmark's - 1 Trung Huynh - 1 Huynh - 1
Top related locs:
Swiss Novo San Antonio Spain San Diego
Top related orgs:
Novo Nordisk - 2 Viking Therapeutics - 2 Food and Drug Administration - 2 UBS - 1 HSBC Global Research - 1 Carmot Therapeutics - 1 Viking - 1 European Association for - 1

Search resuls for: "Justin Zelin"


3 mentions found


☆ These drugmakers are catching up to Eli Lilly and Novo Nordisk in weight loss treatments
  + stars: | 2024-07-28 | by ( Christina Cheddar Berk | In | ) www.cnbc.com   time to read: +6 min
With billions at stake, that's pretty much been a guarantee facing the current market leaders, Eli Lilly and Novo Nordisk , from the start. Their updates are likely to be joined by others in the coming months even as today's incumbents develop their own next-generation weight loss treatments. Other analysts have also grown more optimistic about the future of weight loss treatments. Orforglipron, a once-a-day oral GLP-1 drug that Lilly is working on, had shown a 3% weight loss at 4 weeks. The company is also exploring whether the weight loss treatment could be given only once a month.
Persons: Eli Lilly, drugmakers Roche, Lilly, Denmark's, Trung Huynh, Huynh, Rajesh Kumar, Kumar, Novo, Roche, Roche ADRs, Justin Zelin, Zelin, Viking's, HSBC's Kumar, Novo aren't, —, Nick Wells Organizations: Novo Nordisk, Viking Therapeutics, UBS, HSBC Global Research, Carmot Therapeutics, Food and Drug Administration, Viking, European Association for, Diabetes, Pfizer, Amgen, Therapeutics Locations: Swiss, Novo, San Antonio, Spain
☆ Viking Therapeutics stock jumps 30% after drugmaker moves weight loss injection to late-stage trial
  + stars: | 2024-07-25 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Shares of Viking Therapeutics jumped more than 30% on Thursday after the biotech company a day earlier announced plans to advance its experimental weight loss injection into a late-stage trial earlier than expected. Viking is one of several small and large drugmakers hoping to compete in the space against Novo Nordisk and Eli Lilly , whose weight loss and diabetes GLP-1s have skyrocketed in demand over the last two years. During the call, Lian added that Viking expects to test VK2735 as a monthly injection in a future study. Viking Therapeutics' drug promotes weight loss by targeting a GLP-1 and another hormone called GIP. That pill caused 3.3% weight loss when compared to a placebo in an early-stage trial.
Persons: Eli Lilly, Viking, Brian Lian, Lian, Justin Zelin, Zelin, Eli Lilly's Zepbound Organizations: Viking Therapeutics, San, Novo Nordisk, Food and Drug Administration, FDA, Novo Nordisk's Wegovy Locations: San Diego
☆ Viking joins obesity drug race after promising early trial data
  + stars: | 2023-03-28 | by ( Mariam Esunny | ) www.reuters.com   time to read: +2 min
March 28 (Reuters) - Viking Therapeutics Inc's (VKTX.O) experimental obesity drug helped reduce weight and was safe in an early-stage study, the company said on Tuesday, sparking a 60% rise in its shares. While Novo Nordisk (NOVOb.CO) already has its obesity drug, Wegovy, in the market, Eli Lilly is expecting approval for its treatment later this year. That could also make Viking a potential acquisition target, Laidlaw & Company analyst Yale Jen said. Viking said it was planning to test higher doses of the drug over a longer treatment window in a mid-stage trial, versus a shorter limit in the current, early-stage trial. Shares of Viking were trading at $14.15, bringing the drugmaker closer to a market capitalization of $1 billion.
0 next >>
Total: 3